Loss of methylthioadenosine phosphorylase and elevated ornithine decarboxylase is common in pancreatic cancer

Clinical Cancer Research

Volumn 10, Issue 21, 2004, Pages 7290-7296

  Subhi, Ahmad L ^a   Tang, Baiqing ^a   Balsara, Binaifer R ^a   Altomare, Deborah A ^a   Testa, Joseph R ^a   Cooper, Harry S ^a   Hoffman, John P ^a   Meropol, Neal J ^a   Kruger, Warren D ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5' METHYLTHIOADENOSINE PHOSPHORYLASE; DNA; METHYLTHIOADENOSINE; ORNITHINE DECARBOXYLASE; PHOSPHORYLASE; POLYAMINE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; CHROMOSOME 9P; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; MTAP GENE; NEUROENDOCRINE TUMOR; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

ADENOCARCINOMA; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CHROMOSOMES, HUMAN, PAIR 9; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MODELS, BIOLOGICAL; NEUROENDOCRINE TUMORS; ORNITHINE DECARBOXYLASE; PANCREATIC NEOPLASMS; POLYAMINES; PURINE-NUCLEOSIDE PHOSPHORYLASE;

EID: 8444235920     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0972     Document Type: Article

References (25)

1. Census USBo Statistical abstract of the United States. Washington, DC: US Census Bureau; 2003.
2. Yeo CJ. Neoplasms of the endocrine pancreas. In: Greenfield LJ, Mulholland MW, Oldham KT, Zelenock GB, and Lillemoe KD, editors. Surgery: scientific principles and practice. Philadelphia: Lippincott Williams and Wilkins: 2001.
3. Alexander HR, Jensen RT. Pancreatic Endocrine Tumors. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer principles and practice of oncology. New Haven, CT: Lippincott Williams & Wilkins: 2002.
4. Phan GQ, Yeo CJ, Hruban RH, Lillemoe KD, Pitt HA, Cameron JL. Surgical experience with pancreatic and peripancreatic neuroendocrine tumors: review of 125 patients. J Gustrointest Surg 1998;2:472-82.
5. Nobori T, Karras JG, Della Ragione F, Waltz TA, Chen PP, Carson DA. Absence of methylthioadenosine phosphorylase in human gliomas. Cancer Res 1991;51:3193-7.
6. Garcia-Castellano JM, Villanueva A, Healey JH, et al. Methylthioadenosine phosphorylase gene deletions are common in osteosarcoma. Clin Cancer Res 2002;8:782-7.
7. Behrmann I, Wallner S, Komyod W, et al. Characterization of methylthioadenosin phosphorylase (MTAP) expression in malignant melanoma. Am J Pathol 2003;163:683-90.
8. Schmid M, Malicki D, Nobori T, et al. Homozygous deletions of methylthioadenosine phosphorylase (MTAP) are more frequent than p16INK4A (CDKN2) homozygous deletions in primary non-small cell lung cancers (NSCLC). Oncogene 1998;17:2669-75.
9. M'Soka TJ, Nishioka J, Taga A, et al. Detection of methylthioadenosine phosphorylase (MTAP) and p16 gene deletion in T cell acute lymphoblastic leukemia by real-time quantitative PCR assay. Leukemia 2000;14:935-40.
10. Nobori T, Takabayashi K, Tran P, et al. Genomic cloning of methylthioadenosine phosphorylase: a purine metabolic enzyme deficient in multiple different cancers. Proc Natl Acad Sci USA 1996;93:6203-8.
11. Brat DJ, James CD, Jedlicka AE, et al. Molecular genetic alterations in radiation-induced astrocytomas. Am J Pathol 1999;154:1431-8.
12. Christopher SA, Diegelman P, Porter CW, Kruger WD. Methylthioadenosine phosphorylase, a gene frequently codeleted with p16(cdkN2a/ARF), acts as a tumor suppressor in a breast cancer cell line. Cancer Res 2002;62:6639-44.
13. Subhi AL, Diegelman P, Porter CW, et al. Methylthioadenosine phosphorylase regulates ornithine decarboxylase by production of downstream metabolites. J Biol Chem 2003;278:49868-73.
14. Moshier JA, Dosescu J, Skunca M, Luk GD. Transformation of NIH/3T3 cells by ornithine decarboxylase overexpression. Cancer Res 1993;53:2618-22.
15. O'Brien TG, Megosh LC, Gilliard G, Soler AP. Ornithine decarboxylase overexpression is a sufficient condition for tumor promotion in mouse skin. Cancer Res 1997;57:2630-7.
16. Bell DW, Taguchi T, Jenkins NA, et al. Chromosomal localization of a gene, GF1, encoding a novel zinc finger protein reveals a new syntenic region between man and rodents. Cytogenet Cell Genet 1995;70:263-7.
17. Chen ZH, Olopade OI, Savarese TM. Expression of methylthioadenosine phosphorylase cDNA in p16-, MTAP-malignant cells: restoration of methylthioadenosine phosphorylase-dependent salvage pathways and alterations of sensitivity to inhibitors of purine de novo synthesis. Mol Pharmacol 1997;52:903-11.
18. Nielsen GP, Stemmer-Rachamimov AO, Shaw J, Roy JE, Koh J, Louis DN. Immunohistochemical survey of p16INK4A expression in normal human adult and infant tissues. Lab Investig 1999;79:1137-43.
19. Meyskens FL Jr., Gerner EW. Development of difluoromethylornithine (DFMO) as a chemoprevention agent. Clin Cancer Res 1999;5:945-51.
20. Caldas C, Hahn SA, da Costa LT, et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994;8:27-32.
21. Muerkoster S, Wegehenkel K, Arlt A, et al. Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin-1beta. Cancer Res 2004;64:1331-7.
22. Hori H, Tran P, Carrera CJ, et al. Methylthioadenosine phosphorylase cDNA transfection alters sensitivity to depletion of purine and methionine in A549 lung cancer cells. Cancer Res 1996;56:5653-8.
23. Tang B, Li YN, Kruger WD. Defects in methylthioadenosine phosphorylase are associated with but not responsible for methionine-dependent tumor cell growth. Cancer Res 2000;60:5543-7.
24. O'Shaughnessy JA, Demers LM, Jones SE, et al. Alpha- difluoromethylornithine as treatment for metastatic breast cancer patients. Clin Cancer Res 1999;5:3438-44.
25. Yang Z, Wang J, Yoshioka T, et al. Pharmacokinetics, methionine depletion, and antigenicity of recombinant methioninase in primates. Clin Cancer Res 2004;10:2131-8.